Monopar Therapeutics MNPR 深 滬
交易中 12-24 10:06:33 美东时间
72.05
+1.550
+2.20%
華盛通- 最 高72.07
- 今 開70.26
- 成交量 2.26万股
- 最 低 69.39
- 昨 收 70.50
- 總市值 5.19亿
- 52周最高 105.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 21.00
- 委 比 -99.22%
- 總股本 720.44万
- 歷史最高 240.00
- 量 比 1.69
- 振 幅 3.80%
- 歷史最低 1.3695
- 每 手 1
- 風險率 21.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.45) by 7.38 percent. This is a 29.73 percent decrease over losses of $(0.37) per share
11-13 21:06
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
Monopar Therapeutics Inc. presented new data from the Phase 2 ALXN1840-WD-204 study at the AASLD Liver Meeting 2025, showing that ALXN1840 (tiomolybdate choline) improved copper balance in Wilson disease patients through increased fecal copper excretion. Results from 8 patients demonstrated significant improvement during the 15 mg once-daily dosing period and throughout the entire treatment duration. Additional supporting data will also be presen...
11-09 14:00
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
Monopar Therapeutics Inc. announced that its Phase 2 ALXN1840-WD-204 copper balance study abstract has been selected for oral presentation at the AASLD Liver Meeting 2025. The session, titled "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline," will take place on November 9, 2025, at 9:00-9:15 am EST. For more details, visit the conference website or www.monopartx.com.
10-15 12:00
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125
Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $125.
10-13 20:05
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
Oppenheimer Maintains Outperform on Monopar Therapeutics, Raises Price Target to $115
Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperform and raises the price target from $77 to $115.
10-02 21:31
